BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization

Related Keywords

Boston , Massachusetts , United States , Matt Pera , Inozyme Pharma , Stefan Riley , Company Or Inozyme , Corporate Communications , Twitter , Nasdaq , Inozyme Pharma Inc , Facebook , Stock Incentive Plan , Nasdaq Listing Rule , Senior Director ,